circadian rhythm comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
== Antiquity == [...] as after the death of Oenotrius, Oenotria had another name, and was called Italy, and Morgetia, and after this name it was called Sicily, Chonia, Iapigia, and Salentia, and afterwards cogionta in a name it was called Magna Graecia. According to the Greeks, the region was inhabited before colonization by several communities, including the Ausones-Oenotrians (vine-growers), the Italians, Morgetes, Sicels, and Chone. It is said that the mythical ruler Italus called Calabria “Italy”. Italus was ostensibly present in the first half of the 15th century BCE. Antiochus of Syracuse, the first historian of the West, depicted him as “A good and wise king, capable of subduing neighboring peoples making use of persuasion and force from time to time”.
=== Insects as a novel protein source for pet food === A challenge that is presented when feeding companion animals with food intolerance or sensitivities is finding protein sources that will not irritate their gastrointestinal tracts. Animal protein is a major cause of gastrointestinal problems, and insect protein may be an alternative source for these pets. Insects have the potential to be used as a novel protein in diets for sensitive animals. A novel protein is a protein source to which the animal has not previously been exposed. There are some risks to using novel protein sources, such as contaminants, antinutritional factors (ANFs), and allergens which are not well known. When referring specifically to dog and cat nutrition, the use of alternative protein sources must be able to deliver the ten essential amino acids (EAA) that are not synthesized from the body (including Arg, His, Ile, Leu, Lys, Met, Phe, Thr, Trp and Val). One additional amino acid which is specific to cats who are obligate carnivores by nature is taurine. This requirement is based on the low enzymatic action of cysteine dioxygenase and cysteine sulphinic acid decarboxylase within feline metabolism, where the competing pathway of pyruvate for an energy source overrides taurine synthesis. McCuster et al. created a study to identify amino acid composition of different insects, specifically addressing the presence of taurine in comparison to the National Research Council's (NRC) minimal requirements (MR) for the dog and cat.
Movat's stain is a pentachrome stain originally developed by Henry Zoltan Movat (1923–1995), a Hungarian-Canadian Pathologist in Toronto in 1955 to highlight the various constituents of connective tissue, especially cardiovascular tissue, by five colors in a single stained slide. In 1972, H. K. Russell, Jr. modified the technique so as to reduce the time for staining and to increase the consistency and reliability of the staining, creating the Russell–Movat stain.
==== Metal-free organic cavity modifiers ==== Most examples of MOF-based catalysis make use of metal ions or atoms as active sites. Among the few exceptions are two nickel- and two copper-containing MOFs synthesized by Rosseinsky and co-workers. These compounds employ amino acids (L- or D-aspartate) together with dipyridyls as struts. The coordination chemistry is such that the amine group of the aspartate cannot be protonated by added HCl, but one of the aspartate carboxylates can. Thus, the framework-incorporated amino acid can exist in a form that is not accessible for the free amino acid. While the nickel-based compounds are marginally porous, on account of tiny channel dimensions, the copper versions are clearly porous. The Rosseinsky group showed that the carboxylic acids behave as Brønsted acidic catalysts, facilitating (in the copper cases) the ring-opening methanolysis of a small, cavity-accessible epoxide at up to 65% yield. Superior homogeneous catalysts exist however. Kitagawa and co-workers have reported the synthesis of a catalytic MOF having the formula [Cd(4-btapa)2(NO3)2]. The MOF is three-dimensional, consisting of an identical catenated pair of networks, yet still featuring pores of molecular dimensions. The nodes consist of single cadmium ions, octahedrally ligated by pyridyl nitrogens. From a catalysis standpoint, however, the most interesting feature of this material is the presence of guest-accessible amide functionalities. The amides are capable of base-catalyzing the Knoevenagel condensation of benzaldehyde with malononitrile.
Sources: en.wikipedia.org
=== Etymology and nomenclature === The term psychedelic was coined by the psychiatrist Humphrey Osmond during written correspondence with author Aldous Huxley (written in a rhyme: "To fathom Hell or soar angelic/Just take a pinch of psychedelic.") and presented to the New York Academy of Sciences by Osmond in 1957. It is irregularly derived from the Greek words ψυχή (psychḗ, meaning 'mind, soul') and δηλείν (dēleín, meaning 'to manifest'), with the intended meaning "mind manifesting" or alternatively "soul manifesting", and the implication that psychedelics can reveal unused potentials of the human mind. The term was loathed by American ethnobotanist Richard Schultes but championed by American psychologist Timothy Leary. Aldous Huxley had suggested his own coinage phanerothyme (Greek phaneroein- "to make manifest or visible" and Greek thymos "soul", thus "to reveal the soul") to Osmond in 1956. Recently, the term entheogen (meaning "that which produces the divine within") has come into use to denote the use of psychedelic drugs, as well as various other types of psychoactive substances, in a religious, spiritual, and mystical context. In 2004, David E. Nichols wrote the following about the nomenclature used for psychedelic drugs:
Skittles are multicolored fruit-flavored lentil-shaped sweets produced and marketed by the Wrigley Company, a division of Mars Inc. Skittles consist of hard sugar shells imprinted with the letter 'S' in lowercase, similar to M&M's which have the letter 'M'. The interior consists mainly of sugar, corn syrup, and hydrogenated palm kernel oil along with fruit juice, citric acid, and natural and artificial flavors. Skittles are sold in a variety of flavor collections, such as Tropical, Wild Berry, Smoothie, and Sour.
== Procedure == The test uses a single fasting blood sample, typically collected in a tube such as an NMR LipoTube or a standard red-top tube, and is processed by commercial laboratories. It's often part of a broader NMR LipoProfile, which also assesses cardiovascular risk through lipoprotein particle numbers (e.g., LDL-P).
=== Etymology === The word tomato comes from the Spanish tomate, which in turn comes from the Nahuatl word tomatl [ˈtomat͡ɬ] . The specific name lycopersicum, meaning 'wolf peach', originated with Galen, who used it to denote a plant that has never been identified. Luigi Anguillara speculated in the 16th century that Galen's lycopersicum might be the tomato, and despite the impossibility of this identification, lycopersicum entered scientific use as a name for the fruit.
In 1998, Firehouse Subs surpassed 10 locations, and later that year opened the first location outside of Florida. In 2000, the founders decided to take a different approach, using consultants to plan franchise growth. They were able to set up financing for potential franchisees. The second wave of franchising began in 2001. In 2011, Firehouse Subs opened its first franchises in the U.S. territory of Puerto Rico, via local franchisee Caribbean Restaurants. By 2012 the company reached 500 locations, ending the year with nearly 600. In July 2016, Firehouse Subs opened its 1,000th location. In 2015, Firehouse Subs opened its first locations in Canada, with its first location opening in Oshawa, Ontario in October with franchisee OnFire Restaurant Group. Currently, the group operates 50 Canadian restaurants, with plans to open a total of 90 in Ontario alone. The chain also launched a loyalty program. In June 2017, Firehouse Subs opened its first airport location at Jacksonville International. In December 2017, the brand's second airport location opened at Orlando International. In April 2018, the chain opened its first on-campus location at Western New England University. In 2020 the chain opened a location at Jacksonville's Baptist Medical Center. On November 15, 2021, Burger King parent Restaurant Brands International announced that it would acquire Firehouse Subs for $1 billion. The acquisition was completed on December 15, 2021. On June 22, 2023, Firehouse Subs opened its first location outside North America in Zurich, Switzerland.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.